Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA Approves Lynparza for 1st-Line Maintenance Therapy in Advanced Ovarian Cancer

By Mike Botta | December 20, 2018

The U.S. Food and Drug Administration (FDA) has approved Lynparza for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (BRCAm) advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy, as detected by an FDA-approved companion diagnostic test.

Lynparza is being jointly developed and commercialized by AstraZeneca and Merck & Co., Inc., which is known as MSD outside the U.S. and Canada. The FDA approval was described by AstraZeneca’s head of oncology Dave Fredrickson as a critical advancement in the goal of helping the ovarian cancer patients achieve long-term remission.

The FDA move marks the the first regulatory approval for a PARP inhibitor in the 1st-line maintenance setting for BRCA-mutated advanced ovarian cancer.

The approval was based on positive results from the pivotal Phase III SOLO-1 trial in which Lynparza reduced the risk of disease progression or death by 70 percent in patients with BRCA-mutated advanced ovarian cancer who were in complete or partial response to platinum-based chemotherapy compared to placebo following platinum-based chemotherapy.

Following Wednesday’s approval, the two companies today announced positive results from the randomized, open-label, controlled, Phase III SOLO-3 trial of Lynparza tablets in 266 patients with relapsed ovarian cancer after two or more lines of treatment.

The SOLO-3 trial was conducted as a post-approval commitment in agreement with the FDA and represented the fourth Phase III trial to demonstrate a positive result for drug. 

Results from the trial showed BRCAm advanced ovarian cancer patients treated with Lynparza following two or more prior lines of chemotherapy demonstrated a “statistically significant and clinically meaningful” improvement in the primary endpoint of objective response rate and the key secondary endpoint of progression-free survival compared to chemotherapy, according to the companies. 

The safety and tolerability profile of Lynparza in SOLO-3 was consistent with previous trials and AstraZeneca and Merck said they plan to discuss the results with the FDA.

“Following on the U.S. approval of Lynparza as first-line maintenance therapy for certain patients with BRCAm advanced ovarian cancer, the results of SOLO-3 further reinforce the efficacy of Lynparza in relapsed patients with (germline BRCAm) advanced ovarian cancer following multiple lines of chemotherapy,” Roy Baynes, chief medical officer, MSD Research Laboratories, said.

In July 2017, AstraZeneca and Merck & Co. announced a global strategic oncology collaboration on Lynparza. Working together, the companies will develop Lynparza and selumetinib in combination with other potential new medicines and as monotherapies.

Selumetinib is a drug that was discovered by Array BioPharma and was licensed to AstraZeneca. It is being investigated for the treatment of various types of cancer, such as non-small cell lung cancer and thyroid cancer. 

Independently, the companies will develop Lynparza and selumetinib in combination with their respective PD-L1 and PD-1 medicines.

AstraZeneca and Merck at present are exploring additional trials in advanced ovarian cancer, including the ongoing GINECO/ENGOTov25 Phase III trial, PAOLA-1. That trial is testing the effect of Lynparza in combination with bevacizumab as a maintenance treatment for patients with newly-diagnosed advanced ovarian cancer, regardless of their BRCA status. Results are expected during the second half of 2019.

(Source: AstraZeneca)


Filed Under: Oncology

 

Related Articles Read More >

Roche in Drug Discovery & Development Pharma 50
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
AstraZeneca
AstraZeneca to scoop up biotech TeneoTwo for up to $1.27 billion
Novartis in the Pharma 50
Novartis announces tislelizumab helped extend median overall survival in first-line advanced esophageal cancer 
Johnson & Johnson Janssen pharmaceutical business in the Pharma 50
Janssen gets positive CHMP opinion for Imbruvica for adults with untreated chronic lymphocytic leukemia

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50